Singapore-based biotech firm Tychan to begin human trials for COVID-19 treatment next week
Tychan is said to begin human clinical trials next week for a potential monoclonal antibody treatment for the COVID-19 infection.
Singapore’s Tychan, a biotechnology firm backed by state investor Temasek Holdings, said it will begin human clinical trials next week for a potential monoclonal antibody treatment for COVID-19.
The first phase of the trial to be conducted on 23 healthy volunteers will take about six weeks to evaluate the safety and tolerability of TY027 – a monoclonal antibody that specifically targets SARS-CoV-2, the virus that causes COVID-19.
Antibodies are generated in the body to fight off infection. Monoclonal antibodies mimic natural antibodies and can be isolated and manufactured in large quantities to treat diseases in patients.
Many scientists and researchers believe antibody-based therapies hold great promise for treating people already infected with the disease.
“We will continue with the fast pace of development as we are conscious that a day saved is a day less of misery,” said Teo Ming Kian, chairman of Tychan. He added that the company reached human trials in four months, when it would usually take 12-18 months.
TY027 is being explored for the treatment of patients with COVID-19 to slow the progression of the disease and accelerate recovery, as well as for its potential to provide temporary protection against infection with SARS-CoV-2.
After passing key milestones in the first phase trial, Tychan will seek approval from the Singapore regulator to expand TY027 to a larger population of COVID-19 volunteer patients to establish its efficacy.
Temasek Holdings is the founding investor of Tychan, which has previously developed therapeutic treatments for Zika and yellow fever.
COVID-19 treatment: Melatonin hormone that regulates sleep-wake cycle may prove effective in managing infection
Clinical registries from Cleveland Clinic also showed that regular use of melatonin was associated with a 30 percent lesser chance of testing positive for COVID-19 even after adjusting for age, smoking history, race, and the presence of comorbidities
Regeneron begins phase III trials of REGN-COV2; here's how antibody cocktail can help COVID-19 patients
Currently, the antibody cocktail, developed by researchers at the University of Maryland School of Medicine and Regeneron, is in the phase 2 treatment trials stage
Endothelial cells could be targeted to restore lung function in COVID-19 patients, suggests study
The study authors also said that drugs targeting endothelial activation should be used to control inflammation and coagulopathy associated with COVID-19